Pharmaceuticals News

IMNN-001 is the first frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer  Enrollment in the...

MALVERN, Pa., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”), a leader in interventional mental health that combines its NeuroStar® TMS...

TORONTO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that the Company will expand its ongoing Phase II trial of LSALT peptide...

Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. on track to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567...

Selected 0.60 mg/m2 as the single dose for the TeLuRide-006 study going forward for patients randomized to EIK1001 treatment, in accord with a recommendation of the independent Data Monitoring...

~ 2026 Second Quarter Net Product Sales of $17.1 Million, Up 78% Year over Year ~ ~ 2026 Second Quarter Non-GAAP Adjusted EBITDA of $2.8 Million ~ ~ Record PEDMARK® Demand Carried into Third...

Once-weekly intravenous treatment was associated with reported improvements in finger function and walking ability, with no adverse events reported during treatment BOSTON, MA, Aug. 11, 2026 (GLOBE...

Dark Horse Consulting Group launches DHCG China, appointing Kang Liu, Ph.D. as Senior Director, Head of China, to guide developers through the IIT pathway.

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 50% versus second quarter of 2025 to approximately $657 millionExpanded CARVYKTI® availability to 348 global sites and 19...

Kailera Therapeutics, Inc., today announced the appointment of Nur Nicholson as Chief Technology Officer, effective August 31, 2026.